title: Management of chronic kidney disease after renal transplantation: is it different from nontransplant patients?
abstract: BACKGROUND
  The Kidney Disease Quality Initiative (K/DOQI) of the National Kidney Foundation has published guidelines for the diagnosis and management of chronic kidney disease (CKD). Renal transplant recipients frequently have CKD and complications similar to native kidney disease patients. The purpose of the present study was to compare the management of CKD complications of transplant recipients and nontransplant patients.
  
  
  METHODS
  Eighty three renal transplant recipients with CKD stages 4T and 5T were compared with 83 nontransplant CKD patients matched by CKD stage.
  
  
  RESULTS
  There were no differences between the groups in serum hemoglobin, prevalence of anemia, and percentage of patients treated with erythropoiesis-stimulating agents, but serum ferritin levels were higher among recipients (186.3 +/- 161.3 vs 119.1 +/- 113.4 ng/mL; P = .003). Mean blood pressure (BP) was similar in both groups but a systolic BP > 130 mm Hg was more frequent among recipients (83.3% vs 72.6%). More recipients were treated with either angiotensin-converting enzyme (ACE)-inhibitors or angiotensin receptor antagonist (43.3% vs 8.4%; P < .001). Low-density lipoprotein cholesterol was lower in recipients (108.9 +/- 30.3 vs 120.8 +/- 39.5 mg/dL; P = .033) and a higher percentage was on statin treatment (44.6% vs 28.9%; P = .053). Serum calcium was higher in transplant recipients (9.5 +/- 0.8 vs 8.9 +/- 0.7 mg/dL; P < .005) and phosphate was lower (3.9 +/- 0.9 vs 4.2 +/- 1.1; P = .043); there were no differences in intact parathyroid hormone blood levels.
  
  
  CONCLUSIONS
  The management of renal transplant recipients is no worse than that of nontransplant patients. However, in both populations, some parameters are far from the target recommended by the guidelines.
authors.affiliation: Department of Nephrology, Hospital Ramón y Cajal, Madrid, Spain. guduld5@hotmail.com
authors.forename: S
authors.initials: S
authors.lastname: Jiménez Alvaro
authors.forename: R
authors.initials: R
authors.lastname: Marcén
authors.forename: J L
authors.initials: JL
authors.lastname: Teruel
authors.forename: A
authors.initials: A
authors.lastname: Fernández Rodríguez
authors.forename: J
authors.initials: J
authors.lastname: Pascual
authors.forename: C
authors.initials: C
authors.lastname: Galeano
authors.forename: J
authors.initials: J
authors.lastname: Villacorta
authors.forename: F J
authors.initials: FJ
authors.lastname: Burgos
authors.forename: J
authors.initials: J
authors.lastname: Ortuño
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001794:Blood Pressure; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D005293:Ferritins / Q000097:blood; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000453:epidemiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000473:pathology / Q000628:therapy*; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D005293:Ferritins